Recursion Pharmaceuticals (RXRX)

• Market cap: $2.25B
• 1 day: 12.37%
• 5 days: 10.80%
• 1 month: 3.17%
• 3 months: 39.55%
• 6 months: -23.69%
• Year to date: -23.16%
• 1 year: -25.14%
• 5 years: -82.30%
• 10 years: -82.30%
• Sector: Healthcare
• Industry: Biotechnology

About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Employees: 800

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

106% more repeat investments, than reductions

Existing positions increased: 138 | Existing positions reduced: 67

61% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 41

30% more call options, than puts

Call options by funds: $28.3M | Put options by funds: $21.7M

7% more funds holding

Funds holding: 312 [Q4 2024] → 333 (+21) [Q1 2025]

2.41% less ownership

Funds ownership: 79.42% [Q4 2024] → 77.01% (-2.41%) [Q1 2025]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q4 2024] → 9 (-1) [Q1 2025]

22% less capital invested

Capital invested by funds: $2.06B [Q4 2024] → $1.61B (-$451M) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 10% downside
• Avg. target: $6.50 17% upside
• High target: $8 44% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Morgan Stanley Vikram Purohit	10% downside $5	Equal-Weight Assumed	3 Jul 2025
Needham Gil Blum	44% upside $8	Buy Maintained	6 May 2025